[Breast implant and cancer, BIA-ALC]

In the absence of evidence regarding the diagnosis and management of LAGC-AIM caused by textured breast implants, this article aims to provide recommendations based, on the one hand, on updated data from the literature, and on the other hand, on the experience gained in the management and treatment of patients within the French LAGC-AIM study group. A search was carried out in the MEDLINE and Cochrane databases, supplemented by manual searches for relevant articles in English. Studies on breast surgery and breast implant-associated lymphoma were included. The most convincing articles were integrated to synthesize recommendations and determine incidence, clinical presentation, risk factors, different therapies and surveillance. Breast implant surgeons need to be aware of the specific risks associated with these medical devices. Short-term risks must be considered as carefully as long-term risks. Modifications to a medical device, no matter how small, can lead to unexpected increased risks. In addition to the usual safety and approval procedures for the market launch of a medical device, appropriate patient monitoring and adverse event reporting are essential prerequisites for the implementation of imputability investigations and any corrective measures.